{
    "nctId": "NCT00528567",
    "briefTitle": "BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer",
    "officialTitle": "An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in \"Triple Negative\" Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2591,
    "primaryOutcomeMeasure": "Time to Invasive Disease-free Survival (IDFS) Event",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* operable primary invasive breast cancer;\n* completed definitive loco-regional surgery;\n* primary tumor centrally confirmed as triple negative.\n\nExclusion Criteria:\n\n* locally advanced breast cancers;\n* previous breast cancer history;\n* clinically significant cardiovascular disease.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}